Canopy Growth Reports FY2026: Net Revenue C$284.6M, Q4 Net Revenue C$71.2M, Net Cash C$131.3M
I'm LongbridgeAI, I can summarize articles.Canopy Growth reported FY2026 net revenue of C$284.6M and Q4 revenue of C$71.2M, ending with a net cash position of C$131.3M following strategic recapitalization. The company narrowed its net loss to C$262.9M for the year and posted an adjusted EBITDA loss of C$20.2M. Management anticipates positive adjusted EBITDA in FY2027 driven by cost discipline and acquisition integrations. Key growth drivers included strong performance in Canadian medical and adult-use cannabis segments.
Canopy Growth reported consolidated net revenue of C$71.2 million for Q4 FY2026 and C$284.6 million for the full fiscal year, with the company ending FY2026 with a net cash position of C$131.3 million following a strategic recapitalization. The company narrowed its net loss from continuing operations to C$262.9 million for FY2026 and delivered an adjusted EBITDA loss of C$20.2 million for the year. Management expects positive adjusted EBITDA in FY2027 as cost discipline and integration of recent acquisitions drive improvements.
Financial Highlights
- Q4 FY2026 consolidated net revenue: C$71.2 million (up 10% year-over-year).
- FY2026 consolidated net revenue: C$284.6 million (up 6% versus FY2025).
- Gross margin (as reported) Q4 FY2026: 12%; FY2026: 24% (FY2025: 16% and 30% respectively).
- Net loss from continuing operations FY2026: C$262.9 million; Q4 FY2026 net loss from continuing operations: C$154.7 million.
- Adjusted EBITDA loss FY2026: C$20.2 million; Adjusted EBITDA loss Q4 FY2026: C$6.3 million.
- Net cash position at March 31, 2026: C$131.3 million (improvement from net debt of C$172.6 million at March 31, 2025).
Business Highlights
- Canada medical cannabis delivered strong growth: Q4 medical net revenue up 27% year-over-year and full-year medical revenue up 18%, driven by more insured patients and expanded product assortment.
- Canada adult-use cannabis grew 20% year-over-year for FY2026, with product innovation momentum in vapes, infused pre-roll joints and new all-in-one vaporizers contributing to growth.
- International markets cannabis rebounded in Q4 with net revenue up 68% year-over-year as supply chain issues in Europe were addressed; full-year international cannabis revenue declined 7% versus prior year due to earlier supply constraints.
- Completed acquisition of MTL Cannabis, positioning the company as Canada’s leading medical cannabis provider by revenue and prompting an inventory review that led to acquisition-related inventory charges.
- Storz & Bickel launched the VEAZY portable vaporizer in September 2025; Storz & Bickel net revenue declined 14% in FY2026 versus FY2025 amid softer consumer demand and geographic mix shifts.
Original SEC Filing: Canopy Growth Corp [ CGC ] - 8-K - Jun. 15, 2026